Last reviewed · How we verify

NCT00445107: STAR

SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363)

Completed Phase 3 Last updated 15 August 2024
What this trial tests

Phase 3 trial testing MK0476, montelukast sodium / Duration of Treatment: 8 Weeks in Asthma in 198 participants. Completed in 17 May 2006.

Timeline
1 November 2005
Primary endpoint
1 May 2006
17 May 2006

Quick facts

Lead sponsorOrganon and Co
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment198
Start date1 November 2005
Primary completion1 May 2006
Estimated completion17 May 2006

Drugs / interventions tested

Conditions studied

Sponsor

Organon and Co — full company profile →

Who can join

Adults 15 to 80, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the treatment effect of montelukast 10mg on the primary endpoint of Asthma Control Questionnaire(ACQ), over a 8-week period, in persistent asthma patients with or without allergic rhinitis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

Other Organon and Co trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00445107.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing